title: Mechanisms underlying and medical management of L-Dopa-associated motor complications.
authors.forename: Manfred
authors.initials: M
authors.lastname: Gerlach
authors.forename: Peter
authors.initials: P
authors.lastname: Riederer
authors.forename: Dieter
authors.initials: D
authors.lastname: Scheller
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa
references.citation: J Neural Transm (Vienna). 2011 Dec;118(12):1691-702
references.pmid: 21881838
references.citation: Drugs Today (Barc). 2010 Jul;46(7):483-505
references.pmid: 20683503
references.citation: Mov Disord. 2010 Jul 30;25(10):1357-63
references.pmid: 20198649
references.citation: Drugs. 1998;55 Suppl 1:1-9
references.pmid: 9483164
references.citation: J Neural Transm (Vienna). 2011 Dec;118(12):1727-32
references.pmid: 21274579
references.citation: Mov Disord. 2005;20 Suppl 11:S11-6
references.pmid: 15822109
references.citation: J Neural Transm (Vienna). 2011 Dec;118(12):1703-16
references.pmid: 21161716
references.citation: J Neural Transm (Vienna). 2011 Dec;118(12):1733-42
references.pmid: 21253782
references.citation: Expert Opin Pharmacother. 2006 Sep;7(13):1715-30
references.pmid: 16925499
references.citation: J Neural Transm (Vienna). 2011 Dec;118(12):1717-25
references.pmid: 21188436
references.citation: J Neural Transm (Vienna). 2011 Dec;118(12):1661-90
references.pmid: 21881839